There is good news for diabetics as researchers have developed a pain-free skin patch containing dissolvable compounds that responds to blood chemistry to manage glucose automatically.
For millions of people with type 2 diabetes, ongoing vigilance over the amount of sugar, or glucose, in their blood is the key to health. A finger prick before mealtimes and maybe an insulin injection is an uncomfortable but necessary routine.
The new study, published online in the journal Nature Communications, showed that the biochemical formula of mineralised compounds in the patch responds to sugar levels for days at a time.
In a proof-of-concept study performed with mice, the researchers showed that the biochemically formulated patch of dissolvable microneedles can make the management of Type-2 diabetes much easier.
"This experimental approach could be a way to take advantage of the fact that persons with Type-2 diabetes can still produce some insulin," said Richard Leapman of National Institute of Biomedical Imaging and Bioengineering (NIBIB), part of National Institutes of Health (NIH), US.
"A weekly microneedle patch application would also be less complicated and painful than routines that require frequent blood testing," Leapman said.
The base of the experimental patch is material called alginate, a gum-like natural substance extracted from brown algae.
It is mixed with therapeutic agents and poured into a microneedle form to make the patch.
"Alginate is a pliable material -- it is soft, but not too soft," said lead researcher Xiaoyuan (Shawn) Chen of NIBIB.
"It has to be able to poke the dermis, and while not a commonly used material for needles, it seems to work pretty well in this case," Chen said.
Chen's team infused the alginate with a formula of biochemical particles that stimulates the body's own insulin production when needed and curtails that stimulation when normal blood sugar concentration is reached.
The responsive delivery system of the patch can meet the body's need for days instead of being used up all at once, the study said.
Insulin is a hormone made in the pancreas and secreted into the bloodstream to regulate glucose in response to food intake.
It is needed to move glucose from the bloodstream into cells where the sugar can be converted to energy or stored.
In Type-1 diabetes, usually diagnosed in children and young adults, the body does not make insulin at all.
Type-2 diabetes, which can be diagnosed at any age but more commonly as an adult, progressively lessens the body's ability to make or use insulin.
Untreated, diabetes can result in both vascular and nerve damage throughout the body, with debilitating impacts on the eyes, feet, kidneys, and heart.
Global incidence of all types of diabetes is about 285 million people, of which 90 per cent have Type-2 diabetes.
Many require insulin therapy that is usually given by injection just under the skin in amounts that are calculated according to the deficit in naturally generated insulin in the blood. Insulin therapy is not managed well in half of all cases.
The alternate therapy approach developed by NIBIB researchers may eventually make management of Type-2 diabetes a lot more convenient.
--IANS
gb/vm
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
